Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Gastroenterology
Published in: BMC Gastroenterology 1/2013

Open Access 01-12-2013 | Research article

Psychiatric treatment considerations with direct acting antivirals in hepatitis C

Authors: Sanjeev Sockalingam, Alice Tseng, Pierre Giguere, David Wong

Published in: BMC Gastroenterology | Issue 1/2013

Login to get access

Abstract

Background

Despite recent advances in hepatitis C (HCV) treatment, specifically the addition of direct acting antivirals (DAAs), pegylated interferon-alpha remains the backbone of HCV therapy. Therefore, the impact of DAAs on the management of co-morbid psychiatric illness and neuropsychiatric sequalae remains an ongoing concern during HCV therapy. This paper provides a review of the neuropsychiatric adverse effects of DAAs and drug-drug interactions (DDIs) between DAAs and psychiatric medications.

Methods

We conducted a Pubmed search using relevant search terms and hand searched reference lists of related review articles. In addition, we searched abstracts for major hepatology conferences and contacted respective pharmaceutical companies for additional studies.

Results

Limited data is available on the neuropsychiatric adverse effects of DAAs; however, data from major clinical trials suggest that DAAs have minimal neuropsychiatric risk. DAAs can potentially interact with a variety of psychotropic agents via cytochrome P450 and p-glycoprotein interactions. Triazolam, oral midazolam, St. John’s Wort, carbamazepine and pimozide, are contraindicated with DAAs. DDIs between DAAs and antidepressants, anxiolytics, hypnotics, mood stabilizers, antipsychotics and treatments for opioid dependence are summarized.

Conclusions

Although DAAs do not add significant neuropsychiatric risk, the potential for DDIs is high. Consideration of DDIs is paramount to improving medication adherence and mitigating adverse effects during HCV therapy.
Literature
1.
Wasley A, Alter MJ: Epidemiology of hepatitis C: geographic differences and temporal trends. Semin Liver Dis. 2000, 20 (1): 1-16. 10.1055/s-2000-9506.PubMed
2.
Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL, Haussinger D, Diago M, Carosi G, Dhumeaux D: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002, 347 (13): 975-982. 10.1056/NEJMoa020047.PubMed
3.
Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK: Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001, 358 (9286): 958-965. 10.1016/S0140-6736(01)06102-5.PubMed
4.
Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, Muir AJ, Ferenci P, Flisiak R: Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011, 364 (25): 2405-2416. 10.1056/NEJMoa1012912.PubMed
5.
Poordad F, McCone J, Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, Reddy KR, Goodman ZD, Boparai N: Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011, 364 (13): 1195-1206. 10.1056/NEJMoa1010494.PubMedPubMedCentral
6.
El-Sarag HB, Kunik M, Richardson P, Rabaneck L: Psychiatric disorders among veterans with hepatitis C infection. Gastroenterology. 2002, 123: 476-482. 10.1053/gast.2002.34750.
7.
Yovtcheva SP, Rifai MA, Moles JK, Linden BJV: Psychiatric comorbidity among hepatitis C-positive patients. Psychosomatics. 2001, 42: 411-415. 10.1176/appi.psy.42.5.411.PubMed
8.
Horikawa N, Yamazaki T, Izumi N, Uchihara M: Incidence and clinical course of major depression in patients with chronic hepatitis type C undergoing interferon-alpha therapy: a prospective study. Gen Hosp Psych. 2003, 25: 34-38. 10.1016/S0163-8343(02)00239-6.
9.
Morasco BJ, Loftis JM, Indest DW, Ruimy S, Davison JW, Felker B, Hauser P: Prophylactic antidepressant treatment in patients with hepatitis C on antiviral therapy: a double-blind, placebo-controlled trial. Psychosomatics. 2010, 51 (5): 401-408.PubMedPubMedCentral
10.
Morasco BJ, Rifai MA, Loftis JM, Indest DW, Moles JK, Hauser P: A randomized trial of paroxetine to prevent interferon-alpha-induced depression in patients with hepatitis C. J Affect Disord. 2007, 103: 83-90. 10.1016/j.jad.2007.01.007.PubMed
11.
Hauser P, Khosla J, Aurora H, Laurin J, Kling MA, Hill J, Gulati M, Thornton AJ, Schultz RL, Valentine AD: A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C. Mol Psychiatry. 2002, 7 (9): 942-947. 10.1038/sj.mp.4001119.PubMed
12.
Dieperink E, Ho SB, Tetrick L, Thuras P, Dua K, Willnebring ML: Suicidal ideation during interferon-alpha2b and ribavirin treatment of patients with chronic hepatitis C. Gen Hosp Psych. 2004, 26: 237-240. 10.1016/j.genhosppsych.2004.01.003.
13.
Ademmer K, Beutel M, Bretzel R, Jaeger C, Reimer C: Suicidal ideation with IFN-alpha and ribavirin in a patient with hepatitis C. Psychosomatics. 2001, 42 (4): 365-367. 10.1176/appi.psy.42.4.365.PubMed
14.
Sockalingam S, Links PS, Abbey SE: Suicide risk in hepatitis C and during interferon-alpha therapy: a review and clinical update. J Viral Hepat. 2011, 18 (3): 153-160. 10.1111/j.1365-2893.2010.01393.x.PubMed
15.
Schaefer M, Hintzpeter A, Mohmand A, Janssen G, Pich M, Schwaiger M, Sarkar R, Friebe A, Heinz A, Kluschke M: Hepatitis C treatment in "difficult-to-treat" psychiatric patients with pegylated interferon-alpha and ribavirin: response and psychiatric side effects. Hepatology. 2007, 46: 991-998. 10.1002/hep.21791.PubMed
16.
Neri S, Bertino G, Petralia A, Giancarlo C, Rizzotto A, Calvagno GS, Mauceri B, Abate G, Boemi P, Di Pino A: A multidisciplinary therapeutic approach for reducing the risk of psychiatric side effects in patients with chronic hepatitis C treated with pegylated interferon alpha and ribavirin. J Clin Gastroenterol. 2010, 44 (9): e210-217. 10.1097/MCG.0b013e3181d88af5.PubMed
17.
Moore DJ, Blackstone K, Woods SP, Ellis RJ, Atkinson JH, Heaton RK, Grant I: Methamphetamine use and neuropsychiatric factors are associated with antiretroviral non-adherence. AIDS Care. 2012, 24 (12): 1504-1513. 10.1080/09540121.2012.672718.PubMedPubMedCentral
18.
Vertex Pharmaceuticals Inc: Incivek (telaprevir) Product Monograph. 2012, Cambridge, MA: Vertex Pharmaceuticals Incorporated
19.
Merck Canada Inc: Victrelis (boceprevir) Product Monograph. January 16, 2013, Kirkland, QC: Merck Canada Inc
20.
Kunze A, Huwyler J, Camenisch G, Gutmann H: Interaction of the antiviral drug telaprevir with renal and hepatic drug transporters. Biochem Pharmacol. 2012, 84 (8): 1096-1102. 10.1016/j.bcp.2012.07.032.PubMed
21.
Guengerich FP: Cytochrome P450s and other enzymes in drug metabolism and toxicity. AAPS J. 2006, 8 (1): E101-111. 10.1208/aapsj080112.PubMedPubMedCentral
22.
Flockhart DA, Tanus-Santos JE: Implications of cytochrome P450 interactions when prescribing medication for hypertension. Arch Intern Med. 2002, 162 (4): 405-412. 10.1001/archinte.162.4.405.PubMed
23.
Kipp G, Mohammad R, Lin A, Johnson H: Evaluation of pharmacist identified and mitigated drug-drug interactions in hepatitis C virus infected patients starting telaprevir or boceprevir. The 63rd Annual Meeting of the American Association for the Study of Liver Diseases. 2012, Boston, MA
24.
Hulskotte EGJ, Feng H-P, Xuan F, van Zutven M, O’Mara E, Youngberg S, Wagner JA, Butterton JR: Pharmacokinetic interaction between the HCV protease inhibitor boceprevir and ritonavir-boosted HIV-1 protease inhibitors atazanavir, lopinavir, and darunavir. Clin Infect Dis. 2013, 56 (5): 718-726. 10.1093/cid/cis968.PubMed
25.
Marzolini C, Elzi L, Gibbons S, Weber R, Fux C, Furrer H, Chave JP, Cavassini M, Bernasconi E, Calmy A: Prevalence of comedications and effect of potential drug-drug interactions in the Swiss HIV Cohort Study. Antivir Ther. 2010, 15 (3): 413-423. 10.3851/IMP1540.PubMed
26.
Sockalingam S, Abbey SE: Managing depression during hepatitis C treatment. Can J Psychiatry. 2009, 54 (9): 614-625.PubMed
27.
Schaefer M, Capuron L, Friebe A, Diez-Quevedo C, Robaeys G, Neri S, Foster GR, Kautz A, Forton D, Pariante CM: Hepatitis C infection, antiviral treatment and mental health: A European expert consensus statement. J Hepatol. 2012, 57 (6): 1379-1390. 10.1016/j.jhep.2012.07.037.PubMed
28.
Ramasubbu R, Taylor VH, Saaman Z, Sockalingham S, Li M, Patten S, Rodin G, Schaffer A, Beaulieu S, McIntyre RS: The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and select comorbid medical conditions. Ann Clin Psychiatry. 2012, 24 (1): 91-109.PubMed
29.
Baraldi S, Hepgul N, Mondelli V, Pariante CM: Symptomatic treatment of interferon-alpha-induced depression in hepatitis C: a systematic review. J Clin Psychopharmacol. 2012, 32 (4): 531-543. 10.1097/JCP.0b013e31825d9982.PubMed
30.
Yatham LN, Kennedy SH, Schaffer A, Parikh SV, Beaulieu S, O'Donovan C, MacQueen G, McIntyre RS, Sharma V, Ravindran A: Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. Bipolar Disord. 2009, 11 (3): 225-255. 10.1111/j.1399-5618.2009.00672.x.PubMed
31.
Sherman KE, Flamm SL, Afdhal NH, Nelson DR, Sulkowski MS, Everson GT, Fried MW, Adler M, Reesink HW, Martin M: Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med. 2011, 365 (11): 1014-1024. 10.1056/NEJMoa1014463.PubMed
32.
Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, Focaccia R, Younossi Z, Foster GR, Horban A: Telaprevir for retreatment of HCV infection. N Engl J Med. 2011, 364 (25): 2417-2428. 10.1056/NEJMoa1013086.PubMed
33.
Kwo PY, Lawitz EJ, McCone J, Schiff ER, Vierling JM, Pound D, Davis MN, Galati JS, Gordon SC, Ravendhran N: Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet. 2010, 376 (9742): 705-716. 10.1016/S0140-6736(10)60934-8.PubMed
34.
Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, Poordad F, Goodman ZD, Sings HL, Boparai N: Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med. 2011, 364 (13): 1207-1217. 10.1056/NEJMoa1009482.PubMedPubMedCentral
35.
Schaefer M, Sarkar R, Knop V, Effenberger S, Friebe A, Helnze L, Spengler U, Schlaepfer T, Relmer J, Bugglsch P: Escitalopram for the prevention of peginterferon-alpha2a-associated depression in hepatitis C virus-infected patients without previous psychiatric disease. Ann Intern Med. 2012, 157: 94-103. 10.7326/0003-4819-157-2-201207170-00006.PubMed
36.
Gleason OC, Fucci JC, Yates WR, Philipsen MA: Preventing relapse of major depression during interferon-alpha therapy for hepatitis C–A pilot study. Dig Dis Sci. 2007, 52 (10): 2557-2563. 10.1007/s10620-006-9729-5.PubMed
37.
Hulskotte EGJ, Gupta S, Xuan F, van Zutven MGJA, O'Mara E, Galitz L, Wagner JA, Butterton JR: Coadministration of the HCV protease inhibitor boceprevir has no clinically meaningful effect on the pharmacokinetics of the selective serotonin reuptake inhibitor escitalopram in healthy volunteers. Global Antiviral Journal. 2011, 7 (1): 108-109. abstract
38.
Van Heeswijk RPG, Boogaerts G, De Paepe E, Van Solingen-Ristea R, Garg V, Beaumont M: The pharmacokinetic interaction between escitalopram and the investigational HCV protease inhibitor telaprevir [abstract 12]. Rev Antiviral Ther Infect Dis. 2010, 5: 12-13.
39.
Nichols AI, Behrle JA, Parks V, Richards LS, McGrory SB, Posener J, Patat A, Paul J: Pharmacokinetics, pharmacodynamics, and safety of desvenlafaxine, a serotonin-norepinephrine reupatke inhibitor. J Bioequiv Availab. 2013, 5: 1-
40.
Zhou SF, Lai X: An update on clinical drug interactions with the herbal antidepressant St. John's wort. Current drug metabolism. 2008, 9 (5): 394-409. 10.2174/138920008784746391.PubMed
41.
Maddock C, Baita A, Orru MG, Sitzia R, Costa A, Muntoni E, Farci MG, Carpiniello B, Pariante CM: Psychopharmacological treatment of depression, anxiety, irritability and insomnia in patients receiving interferon-alpha: a prospective case series and a discussion of biological mechanisms. J Psychopharmacol. 2004, 18 (1): 41-46. 10.1177/0269881104040230.PubMed
42.
Dieperink E, Leskela J, Dieperink ME, Evans B, Thuras P, Ho SB: The effect of pegylated interferon-alpha2b and ribavirin on posttraumatic stress disorder symptoms. Psychosomatics. 2008, 49 (3): 225-229. 10.1176/appi.psy.49.3.225.PubMed
43.
Gleason OC, Yates WR, Philipsen MA, Isbell MD, Pollock BG: Plasma levels of citalopram in depressed patients with hepatitis C. Psychosomatics. 2004, 45 (1): 29-33. 10.1176/appi.psy.45.1.29.PubMed
44.
Gleason OC, Yates WR, Isbell MD, Philipsen MA: An open-label trial of citalopram for major depression in patients with hepatitis C. J Clin Psychiatry. 2002, 63 (3): 194-198. 10.4088/JCP.v63n0304.PubMed
45.
Gleason OC, Yates WR, Philipsen MA: Major depressive disorder in hepatitis C: an open-label trial of escitalopram. Prim Care Companion J Clin Psychiatry. 2005, 7 (5): 225-230. 10.4088/PCC.v07n0503.PubMedPubMedCentral
46.
Swinson RP, Antony MM, Bleau P, Chokka P, Craven M, Fallu A, Katzman M, Kjernisted K, Lanius R, Manassis K: Clinical Practice Guidelines: Management of Anxiety DIsorders. Can J Psychiatry. 2006, 51 (8): 2-
47.
Castro VM, Clements CC, Murphy SN, Gainer VS, Fava M, Weilburg JB, Erb JL, Churchill SE, Kohane IS, Iosifescu DV: QT interval and antidepressant use: a cross sectional study of electronic health records. BMJ. 2013, 346: f288-10.1136/bmj.f288.PubMedPubMedCentral
48.
Lundbeck Canada Inc: Celexa (citalopram) Product Monograph. 2012, Montreal, QC: Lundbeck Canada Inc
49.
Lundbeck Canada Inc: Cipralex (escitalopram) Product Monograph. 2012, Montreal, QC: Lundbeck Canada Inc
50.
DeMaio W, Kane CP, Nichols AI, Jordan R: Metabolism studies of desvenlafaxine. J Bioequiv Availab. 2011, 3: 151-160.
51.
Hosoda S, Takimura H, Shibayama M, Kanamura H, Ikeda K, Kumada H: Psychiatric symptoms related to interferon therapy for chronic hepatitis C: clinical features and prognosis. Psychiatry Clin Neurosci. 2000, 54: 565-572. 10.1046/j.1440-1819.2000.00754.x.PubMed
52.
Scalori A, Pozzi M, Bellia V, Apale P, Santamaria G, Bordoni T, Redaelli A, Avolio A, Parravicini P, Pioltelli P: Interferon-induced depression: prevalence and management. Dig Liver Dis. 2005, 37 (2): 102-107. 10.1016/j.dld.2004.09.018.PubMed
53.
Huet PM, Villeneuve JP: Determinants of drug disposition in patients with cirrhosis. Hepatology. 1983, 3 (6): 913-918.PubMed
54.
Kasserra C, Hughes E, Treitel M, Gupta S, O’Mara E: Clinical pharmacology of boceprevir: metabolism, excretion, and drug-drug interactions [abstract 118]. 18th Conference on Retroviruses and Opportunistic Infections. 2011, Boston, USA
55.
Garg V, Chandorkar G, Farmer HF, Smith F, Alves K, Van Heeswijk RPG: Effect of telaprevir on the pharmacokinetics of midazolam and digoxin. J Clin Pharmacol. 2012, 52 (10): 1566-1573. 10.1177/0091270011419850.PubMed
56.
Luo X, Van Heeswijk RPG, Alves K, Garg V: The effect of telaprevir on the pharmacokinetics of alprazolam and zolpidem in healthy volunteers [abstract PK_11]. Rev Antiviral Ther Infect Dis. 2011, 6: 13-
57.
Rifai MA: Hepatitis C treatment of patients with bipolar disorder: a case series. Prim Care Companion J Clin Psychiatry. 2006, 8 (6): 361-366. 10.4088/PCC.v08n0607.PubMedPubMedCentral
58.
Powell-Jackson PR, Tredger JM, Williams R: Hepatotoxicity to sodium valproate: a review. Gut. 1984, 25 (6): 673-681. 10.1136/gut.25.6.673.PubMedPubMedCentral
59.
Felker BL, Sloan KL, Dominitz JA, Barnes RF: The safety of valproic acid use for patients with hepatitis C infection. Am J Psychiatry. 2003, 160 (1): 174-178. 10.1176/appi.ajp.160.1.174.PubMed
60.
Argikar UA, Remmel RP: Variation in glucuronidation of lamotrigine in human liver microsomes. Xenobiotica; the fate of foreign compounds in biological systems. 2009, 39 (5): 355-363. 10.1080/00498250902745082.PubMed
61.
Schaffer A, McIntosh D, Goldstein BI, Rector NA, McIntyre RS, Beaulieu S, Swinson R, Yatham LN: The CANMAT task force recommendations for the management of patients with mood disorders and comorbid anxiety disorders. Ann Clin Psychiatry. 2012, 24 (1): 6-22.PubMed
62.
Novartis Pharmaceuticals Canada Inc: Tegretol (Carbamazepine) Product Monograph. 2011, Dorval, Que: Novartis Pharmaceuticals Canada Inc
63.
Andreasen AH, Brosen K, Damkier P: A comparative pharmacokinetic study in healthy volunteers of the effect of carbamazepine and oxcarbazepine on cyp3a4. Epilepsia. 2007, 48 (3): 490-496. 10.1111/j.1528-1167.2007.00924.x.PubMed
64.
Hachad H, Ragueneau-Majlessi I, Levy RH: New antiepileptic drugs: review on drug interactions. Ther Drug Monit. 2002, 24 (1): 91-103. 10.1097/00007691-200202000-00016.PubMed
65.
Freudenreich O, Gandhi RT, Walsh JP, Henderson DC, Goff DC: Hepatitis C in schizophrenia: screening experience in a community-dwelling clozapine cohort. Psychosomatics. 2007, 48 (5): 405-411. 10.1176/appi.psy.48.5.405.PubMed
66.
Sockalingam S, Shammi C, Powell V, Barker L, Remington G: Determining rates of hepatitis C in a clozapine treated cohort. Schizophr Res. 2010, 124 (1–3): 86-90.PubMed
67.
Matthews AM, Huckans MS, Blackwell AD, Hauser P: Hepatitis C testing and infection rates in bipolar patients with and without comorbid substance use disorders. Bipolar Disord. 2008, 10 (2): 266-270. 10.1111/j.1399-5618.2007.00472.x.PubMed
68.
Telio D, Sockalingam S, Stergiopoulos V: Persistent psychosis after treatment with interferon alfa: a case report. J Clin Psychopharmocol. 2006, 26 (4): 446-447. 10.1097/01.jcp.0000227348.59912.5d.
69.
Thome J, Knopf U: Acute psychosis after injection of pegylated interferon alpha-2a. Eur Psychiatry. 2003, 18: 142-143. 10.1016/S0924-9338(03)00030-0.PubMed
70.
Garcia-Pares G, Domenech C, Gil M: Psychosis induced by interferon-alpha. Psychosomatics. 2002, 43: 428-429. 10.1176/appi.psy.43.5.428.PubMed
71.
Hoffman RG, Cohen MA, Alfonso CA, Weiss JJ, Jones S, Keller M, Condermarin JR, Chiu NM, Jacobson JM: Treatment of interferon-induced psychosis in patients with comorbid hepatitis C and HIV. Psychosomatics. 2003, 44: 417-420. 10.1176/appi.psy.44.5.417.PubMed
72.
Schafer M, Boetsch T, Laakmann G: Psychosis in a methadone-substituted patient during interferon-alpha treatment of hepatitis C. Addiction. 2000, 95 (7): 1101-1104.PubMed
73.
Constant A, Castera L, Dantzer R, Couzigou P, de Ledinghen V, Demotes-Mainard J, Henry C: Mood alterations during interferon-alfa therapy in patients with chronic hepatitis C: evidence for an overlap between manic/hypomanic and depressive symptoms. J Clin Psychiatry. 2005, 66 (8): 1050-1057. 10.4088/JCP.v66n0814.PubMed
74.
Onyike CU, Bonner JO, Lyketsos CG, Treisman GJ: Mania during treatment of chronic hepatitis C with pegylated interferon and ribavirin. Am J Psychiatry. 2004, 161 (3): 429-435. 10.1176/appi.ajp.161.3.429.PubMed
75.
Harrigan EP, Miceli JJ, Anziano R, Watsky E, Reeves KR, Cutler NR, Sramek J, Shiovitz T, Middle M: A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition. J Clin Psychopharmacol. 2004, 24 (1): 62-69. 10.1097/01.jcp.0000104913.75206.62.PubMed
76.
Merck Canada Inc. MC: Saphris (asenapine) Product Monograph. 2013, Kirkland, QC: Merck Canada Inc
77.
Eiermann B, Engel G, Johansson I, Zanger UM, Bertilsson L: The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine. Br J Clin Pharmacol. 1997, 44 (5): 439-446.PubMedPubMedCentral
78.
Spina E, de Leon J: Metabolic drug interactions with newer antipsychotics: a comparative review. Basic Clin Pharmacol Toxicol. 2007, 100 (1): 4-22. 10.1111/j.1742-7843.2007.00017.x.PubMed
79.
English BA, Dortch M, Ereshefsky L, Jhee S: Clinically Significant Psychotropic Drug-Drug Interactions in the Primary Care Setting. Curr Psychiatry Rep. 2012, 14 (4): 376-390. 10.1007/s11920-012-0284-9.PubMedPubMedCentral
80.
AstraZeneca Canada Inc: Seroquel (quetiapine) Product Monograph. 2013, Mississauga, ON: AstraZeneca Canada Inc, April 16
81.
Rajkumar AP, Poonkuzhali B, Kuruvilla A, Jacob M, Jacob KS: Clinical predictors of serum clozapine levels in patients with treatment-resistant schizophrenia. Int Clin Psychopharmacol. 2013, 28 (1): 50-56. 10.1097/YIC.0b013e32835ac9da.PubMed
82.
Liukkonen T, Sorjonen M, Jokelainen J, Timonen M: Treatment of hepatitis C with interferon-alpha and ribavirine in a patient with long-term clozapine treatment. Psychosomatics. 2008, 49 (1): 86-88.PubMed
83.
Boulton DW, DeVane CL, Liston HL, Markowitz JS: In vitro P-glycoprotein affinity for atypical and conventional antipsychotics. Life Sci. 2002, 71 (2): 163-169. 10.1016/S0024-3205(02)01680-6.PubMed
84.
Sylvestre DL, Clements BJ: Adherence to hepatitis C treatment in recovering heroin users maintained on methadone. Eur J Gastroenterol Hepatol. 2007, 19 (9): 741-747. 10.1097/MEG.0b013e3281bcb8d8.PubMed
85.
Grebely J, Knight E, Genoway KA, Viljoen M, Khara M, Elliott D, Gallagher L, Storms M, Raffa JD, DeVlaming S: Optimizing assessment and treatment for hepatitis C virus infection in illicit drug users: a novel model incorporating multidisciplinary care and peer support. Eur J Gastroenterol Hepatol. 2010, 22 (3): 270-277. 10.1097/MEG.0b013e32832a8c4c.PubMed
86.
Luo X, Trevejo J, van Heeswijk RP, Smith F, Garg V: Effect of telaprevir on the pharmacokinetics of buprenorphine in volunteers on stable buprenorphine/naloxone maintenance therapy. Antimicrob Agents Chemother. 2012, 56 (7): 3641-3647. 10.1128/AAC.00077-12.PubMedPubMedCentral
87.
Sockalingam S, Blank D, Al Jarad A, Alosaimi F, Hirschfield G, Abbey SE: A comparison of depression screening instruments in hepatitis C and the impact of depression on somatic symptoms. Psychosomatics. 2011, 52 (5): 433-440.PubMed
88.
Hulskotte EGJ, Hwa-Ping F, Bruce RD, Webster LR, Xuan F, O'Mara E, Wagner JA, Butterton JR: Pharmacokinetic interaction between HCV protease inhibitor boceprevir and methadone or buprenorphine in subjects on stable maintenance therapy [abstract PK_09]. 2012, Cambridge, MA: 7th International Workshop on Clinical Pharmacology of Hepatitis Therapy, Rev Antiviral Ther Infect Dis 2012; 6:12
89.
Dbouk B, Arguedas MR, Sheikh A: Assessment of the PHQ-9 as a screening tool for depression in patients with chronic hepatitis C. Dig Dis Sci. 2008, 53: 1100-1106. 10.1007/s10620-007-9985-z.PubMed
90.
Knott A, Dieperink E, Willenbring ML, Heit S, Durfee JM, Wingert M, Johnson JR, Thuras P, Ho SB: Integrated psychiatric/medical care in a chronic hepatitis C clinic: effect on antiviral treatment evaluation and outcomes. Am J Gastroenterol. 2006, 101 (10): 2254-2262. 10.1111/j.1572-0241.2006.00731.x.PubMed
91.
Huckans M, Mitchell A, Ruimy S, Loftis J, Hauser P: Antiviral therapy completion and response rates among hepatitis C patients with and without schizophrenia. Schizophr Bull. 2010, 36 (1): 165-172. 10.1093/schbul/sbn065.PubMed
92.
Sockalingam S, Blank D, Banga CA, Mason K, Dodd Z, Powis J: A novel program for treating patients with trimorbidity: hepatitis C, severe mental illness, and active substance use. Eur J Gastroenterol Hepatol. 2013, in press,
Metadata
Title
Psychiatric treatment considerations with direct acting antivirals in hepatitis C
Authors
Sanjeev Sockalingam
Alice Tseng
Pierre Giguere
David Wong
Publication date
01-12-2013
Publisher
BioMed Central
Published in
BMC Gastroenterology / Issue 1/2013
Electronic ISSN: 1471-230X
DOI
https://doi.org/10.1186/1471-230X-13-86

Other articles of this Issue 1/2013

BMC Gastroenterology 1/2013 Go to the issue

Research article

Progressive balloon dilatation following hepaticojejunostomy improves outcome of bile duct stricture after iatrogenic biliary injury

Research article

Co-culture of primary human tumor hepatocytes from patients with hepatocellular carcinoma with autologous peripheral blood mononuclear cells: study of their in vitro immunological interactions

Research article

Evaluation of a new fluorescence quantitative PCR test for diagnosing Helicobacter pylori infection in children

Research article

Threaded biliary inside stents are a safe and effective therapeutic option in cases of malignant hilar obstruction

Research article

Preventive effect of irsogladine or omeprazole on non-steroidal anti-inflammatory drug-induced esophagitis, peptic ulcers, and small intestinal lesions in humans, a prospective randomized controlled study

Research article

Prevalence and risk factors of Helicobacter pylori infection in Korea: Nationwide multicenter study over 13 years
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits